# A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

> **NCT06653322** · PHASE3 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 400 (estimated)

## Conditions studied

- Asthma With Eosinophilic Phenotype

## Interventions

- **DRUG:** HR-1703
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06653322
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06653322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06653322, "A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06653322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*